Scribd Logo
Upload

Welcome to Scribd!

  • Pubmed 38268318

    Uploaded by

    prima
    2 views2 pages
    This study estimated the annual healthcare costs of cancer in Belgium using national registry data. The highest average cost per patient was €15,867 for lung cancer. Lung cancer was the most costly cancer overall, with costs of nearly €700 million in 2018. Breast and colorectal cancers each cost over €300 million that year. The direct costs of the most common cancer sites in Belgium were estimated to provide guidance for cost containment policies, as many cancers can be prevented by addressing risk factors like smoking and obesity.

    Original Description:

    Original Title

    pubmed-38268318

    Copyright

    © © All Rights Reserved

    Available Formats

    TXT, PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    Report this Document
    This study estimated the annual healthcare costs of cancer in Belgium using national registry data. The highest average cost per patient was €15,867 for lung cancer. Lung cancer was the most costly cancer overall, with costs of nearly €700 million in 2018. Breast and colorectal cancers each cost over €300 million that year. The direct costs of the most common cancer sites in Belgium were estimated to provide guidance for cost containment policies, as many cancers can be prevented by addressing risk factors like smoking and obesity.

    Copyright:

    © All Rights Reserved
    Download as TXT, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    2 views2 pages

    Pubmed 38268318

    Uploaded by

    prima
    This study estimated the annual healthcare costs of cancer in Belgium using national registry data. The highest average cost per patient was €15,867 for lung cancer. Lung cancer was the most costly cancer overall, with costs of nearly €700 million in 2018. Breast and colorectal cancers each cost over €300 million that year. The direct costs of the most common cancer sites in Belgium were estimated to provide guidance for cost containment policies, as many cancers can be prevented by addressing risk factors like smoking and obesity.

    Copyright:

    © All Rights Reserved
    Download as TXT, PDF, TXT or read online from Scribd
    Flag for inappropriate content
    of 2

    PMID- 38268318

    OWN - NLM
    STAT- Publisher
    LR - 20240125
    IS - 2045-7634 (Electronic)
    IS - 2045-7634 (Linking)
    DP - 2024 Jan 24
    TI - The incremental healthcare cost associated with cancer in Belgium: A
    registry-based data analysis.
    LID - 10.1002/cam4.6659 [doi]
    AB - BACKGROUND: Similar to many countries, Belgium experienced a rapid increase
    in
    cancer diagnoses in the last years. Considering that a large part of cancer
    types
    could be prevented, our study aimed to estimate the annual healthcare burden
    of
    cancer per site, and to compare cost with burden of disease estimates to have
    a
    better understanding of the impact of different cancer sites in Belgium.
    METHODS:
    We used nationally available data sources to estimate the healthcare
    expenditure.
    We opted for a prevalence-based approach which measures the disease
    attributable
    costs that occur concurrently for 10-year prevalent cancer cases in 2018.
    Average
    attributable costs of cancer were computed via matching of cases (patients
    with
    cancer by site) and controls (patients without cancer). Years of life lost
    due to
    disability (YLD) were used to summarize the health impact of the selected
    cancers. RESULTS: The highest attributable cost in 2018 among the selected
    cancers was on average €15,867 per patient for bronchus and lung cancer,
    followed
    by liver cancer, pancreatic cancer, and mesothelioma. For the total cost,
    lung
    cancer was the most costly cancer site with almost €700 million spent in
    2018.
    Lung cancer was followed by breast and colorectal cancer that costed more
    than
    €300 million each in 2018. CONCLUSIONS: In our study, the direct attributable
    cost of the most prevalent cancer sites in Belgium was estimated to provide
    useful guidance for cost containment policies. Many of these cancers could be
    prevented by tackling risk factors such as smoking, obesity, and
    environmental
    stressors.
    CI - © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
    FAU - Gorasso, Vanessa
    AU - Gorasso V
    AUID- ORCID: 0000-0001-6884-9316
    AD - Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
    AD - Department of Public Health and Primary Care, Ghent University, Ghent,
    Belgium.
    FAU - Vandevijvere, Stefanie
    AU - Vandevijvere S
    AD - Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
    FAU - Van der Heyden, Johan
    AU - Van der Heyden J
    AD - Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
    FAU - Pelgrims, Ingrid
    AU - Pelgrims I
    AD - Department of Risk and Health Impact Assessment, Sciensano, Brussels,
    Belgium.
    AD - Department of Applied Mathematics, Computer Science and Statistics, Ghent
    University, Ghent, Belgium.
    FAU - Hilderink, Henk
    AU - Hilderink H
    AD - Centre for Public Health Forecasting, National Institute for Public Health
    and
    the Environment (RIVM), Utrecht, The Netherlands.
    FAU - Nusselder, Wilma
    AU - Nusselder W
    AD - Department of Public Health, Erasmus Medical Center, Rotterdam, The
    Netherlands.
    FAU - Demoury, Claire
    AU - Demoury C
    AD - Department of Risk and Health Impact Assessment, Sciensano, Brussels,
    Belgium.
    FAU - Schmidt, Masja
    AU - Schmidt M
    AD - Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
    FAU - Vansteelandt, Stijn
    AU - Vansteelandt S
    AD - Department of Applied Mathematics, Computer Science and Statistics, Ghent
    University, Ghent, Belgium.
    FAU - De Smedt, Delphine
    AU - De Smedt D
    AD - Department of Public Health and Primary Care, Ghent University, Ghent,
    Belgium.
    FAU - Devleesschauwer, Brecht
    AU - Devleesschauwer B
    AD - Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium.
    AD - Department of Translational Physiology, Infectiology and Public Health, Ghent
    University, Merelbeke, Belgium.
    LA - eng
    PT - Journal Article
    DEP - 20240124
    PL - United States
    TA - Cancer Med
    JT - Cancer medicine
    JID - 101595310
    SB - IM
    OTO - NOTNLM
    OT - burden of disease
    OT - cancer
    OT - cost-of-illness
    EDAT- 2024/01/25 06:44
    MHDA- 2024/01/25 06:44
    CRDT- 2024/01/25 02:12
    PHST- 2023/09/04 00:00 [revised]
    PHST- 2023/05/26 00:00 [received]
    PHST- 2023/10/03 00:00 [accepted]
    PHST- 2024/01/25 06:44 [medline]
    PHST- 2024/01/25 06:44 [pubmed]
    PHST- 2024/01/25 02:12 [entrez]
    AID - 10.1002/cam4.6659 [doi]
    PST - aheadofprint
    SO - Cancer Med. 2024 Jan 24. doi: 10.1002/cam4.6659.

    You might also like